Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Biomarkers Market 2021
Biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. Biomarkers have become vital tools for healthcare and pharmaceutical industries, serving several purposes. The global biomarkers market in terms of revenue is set to grow by US$ 46 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.6% during the forecast period, according to data and analytics company StrategyHelix. Biomarkers are of increasingly high importance in medicine, particularly in the realm of personalized medicine. The factors driving the biomarkers market are increasing demand for personalized medicine, rising government and private funding, increasing prevalence of infectious diseases and various types of cancer globally.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for biomarkers. The global biomarkers market is segmented on the basis of technology, disease, end-user, and region. By technology, it is categorized into genomics, proteomics, metabolomics, imaging, and others. By disease, the biomarkers market is divided into cancer, cardiovascular and metabolic diseases, neurodegenerative diseases, infectious diseases, autoimmune diseases, and others. Based on end-user, the biomarkers market is divided into hospitals and diagnostics, research and academic institutes, biopharmaceutical and biotech companies, and CROs.
The report has profiled some of the key players of the market such as Abbott Laboratories Ltd., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biomarkers market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Technology: genomics, proteomics, metabolomics, imaging, and others
Disease: cancer, cardiovascular and metabolic diseases, neurodegenerative diseases, infectious diseases, autoimmune diseases, and others
End-user: hospitals and diagnostics, research and academic institutes, biopharmaceutical and biotech companies, and CROs
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global biomarkers market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global biomarkers market looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Biomarkers Market by Technology
5. Biomarkers Market by Disease
5.2 Cardiovascular And Metabolic Diseases
5.3 Neurodegenerative Diseases
5.4 Infectious Diseases
5.5 Autoimmune Diseases
6. Biomarkers Market by End-User
6.1 Hospitals And Diagnostics
6.2 Research And Academic Institutes
6.3 Biopharmaceutical And Biotech Companies
7. Biomarkers Market by Region
7.1 North America
7.2 Asia Pacific
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 Abbott Laboratories Ltd.
8.2 Becton, Dickinson and Company
8.3 Bio-Rad Laboratories, Inc.
8.4 Danaher Corporation
8.5 F. Hoffmann-La Roche Ltd
8.6 PerkinElmer, Inc.
8.7 QIAGEN N.V.
8.8 Siemens Healthineers AG
8.9 Thermo Fisher Scientific Inc.
9.1 About StrategyHelix